Last reviewed · How we verify

OraPharma — Portfolio Competitive Intelligence Brief

OraPharma pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Minocycline HCl Microspheres Minocycline HCl Microspheres marketed Tetracycline antibiotic Bacterial 30S ribosome Dentistry / Periodontics
Minocycline HCl Minocycline HCl marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease; Dermatology; Periodontal Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Air Force Specialized Hospital, Cairo, Egypt · 1 shared drug class
  2. Beijing Tiantan Hospital · 1 shared drug class
  3. Chinese University of Hong Kong · 1 shared drug class
  4. Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
  5. Darier · 1 shared drug class
  6. Edward Lain, MD · 1 shared drug class
  7. Galderma R&D · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for OraPharma:

Cite this brief

Drug Landscape (2026). OraPharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orapharma. Accessed 2026-05-15.

Related